Therapies, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)
Опубликована: Июнь 8, 2024
Abstract Pain is estimated to affect more than 20% of the global population, imposing incalculable health and economic burdens. Effective pain management crucial for individuals suffering from pain. However, current methods assessment treatment fall short clinical needs. Benefiting advances in neuroscience biotechnology, neuronal circuits molecular mechanisms critically involved modulation have been elucidated. These research achievements incited progress identifying new diagnostic therapeutic targets. In this review, we first introduce fundamental knowledge about pain, setting stage subsequent contents. The review next delves into underlying disorders, including gene mutation, epigenetic modification, posttranslational inflammasome, signaling pathways microbiota. To better present a comprehensive view research, two prominent issues, sexual dimorphism comorbidities, are discussed detail based on findings. status quo evaluation manipulation summarized. A series improved innovative strategies, such as therapy, monoclonal antibody, brain-computer interface microbial intervention, making strides towards application. We highlight existing limitations future directions enhancing quality preclinical research. Efforts decipher complexities pathology will be instrumental translating scientific discoveries practice, thereby improving bench bedside.
Язык: Английский
Процитировано
30
JAMA Network Open, Год журнала: 2023, Номер 6(5), С. e2312522 - e2312522
Опубликована: Май 9, 2023
Importance The use of cannabis as a medicine is becoming increasingly prevalent. Given the diverse range conditions being treated with medical cannabis, well vast array products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety efficacy. Objective To assess whether patients using report improvements in health-related quality life over time. Design, Setting, Participants This retrospective case series study was conducted at network specialist clinics (Emerald Clinics) located across Australia. were who received treatment for any indication point between December 2018 May 2022. Patients followed up every mean (SD) 44.6 (30.1) days. Data to 15 follow-ups reported. Statistical analysis from August September Exposure Medical cannabis. Product types cannabinoid content varied time accordance treating physician’s judgement. Main Outcomes Measures main outcome measure assessed 36-Item Short Form Health Survey (SF-36) questionnaire. Results In this 3148 patients, 1688 (53.6%) female; 820 (30.2%) employed; age 55.9 (18.7) years baseline before treatment. Chronic noncancer pain most common (68.6% [2160 3148]), by cancer (6.0% [190 insomnia (4.8% [152 anxiety (4.2% [132 3148]). After commencing reported significant relative on all 8 domains SF-36, these mostly sustained controlling potential confounders regression model, associated an improvement 6.60 (95% CI, 4.57-8.63) points 18.31 15.86-20.77) SF-36 scores, depending domain (all P < .001). Effect sizes (Cohen d ) ranged 0.21 0.72. A total 2919 adverse events reported, including 2 that considered serious. Conclusions Relevance study, life, which Adverse rarely serious but common, highlighting need caution prescribing
Язык: Английский
Процитировано
38
Gastroenterology, Год журнала: 2024, Номер 166(6), С. 976 - 994
Опубликована: Фев. 5, 2024
Cofounder of pHarm Therapeutics Inc., a company that is developing pH sensitive analgesics selectively target sites inflammation where pain originates.PCK
Язык: Английский
Процитировано
18
Basic & Clinical Pharmacology & Toxicology, Год журнала: 2024, Номер 134(5), С. 574 - 601
Опубликована: Март 13, 2024
Abstract Studies have demonstrated the neuroprotective effect of cannabidiol (CBD) and other Cannabis sativa L. derivatives on diseases central nervous system caused by their direct or indirect interaction with endocannabinoid system‐related receptors molecular targets, such as 5‐HT 1A receptor, which is a potential pharmacological target CBD. Interestingly, CBD binding receptor may be suitable for treatment epilepsies, parkinsonian syndromes amyotrophic lateral sclerosis, in serotonergic plays key role. The aim this review was to provide an overview cannabinoid effects neurological disorders, epilepsy, multiple sclerosis Parkinson's diseases, discuss possible mechanism action, highlighting interactions targets phytocannabinoids. has been shown significant therapeutic epilepsy disease, while nabiximols contribute reduction spasticity are frequent option sclerosis. Although there theories cannabinoids substantially greater progress search strong scientific evidence effectiveness needed.
Язык: Английский
Процитировано
15
Nature Reviews Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Язык: Английский
Процитировано
2
Addiction, Год журнала: 2025, Номер unknown
Опубликована: Фев. 13, 2025
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related
Язык: Английский
Процитировано
2
JAMA Network Open, Год журнала: 2023, Номер 6(4), С. e239126 - e239126
Опубликована: Апрель 20, 2023
Importance Epilepsy is one of the most common neurologic disorders globally. Cannabidiol (CBD) has been approved for treatment epilepsy, but its use associated with several different adverse events (AEs). Objective To investigate frequency and risk AEs developing in patients epilepsy who are using CBD. Data Sources PubMed, Scopus, Web Science, Google Scholar were searched relevant studies published from database inception up to August 4, 2022. The search strategy included a combination following keywords: ( cannabidiol OR epidiolex ) AND seizures ). Study Selection review all randomized clinical trials that investigated at least 1 AE CBD epilepsy. Extraction Synthesis Basic information about each study was extracted. I 2 statistics calculated Q assess statistical heterogeneity among studies. A random-effects model used cases substantial heterogeneity, fixed-effects if statistic lower than 40%. This conducted according Preferred Reporting Items Systematic Reviews Meta-analyses (PRISMA) guideline. Main Outcomes Measures Frequency Results Nine included. Overall incidences 9.7% group 4.0% control found any grade AEs. overall ratios (RRs) severe 1.12 (95% CI, 1.02-1.23) 3.39 1.42-8.09), respectively, compared group. Compared group, had greater incidence serious (RR, 2.67; 95% 1.83-3.88), resulting discontinuation 3.95; 1.86-8.37), dose reduction 9.87; 5.34-14.40). Because some bias (3 raised concerns 3 high bias), these findings should be interpreted caution. Conclusions Relevance In this systematic meta-analysis trials, treat an increased Additional needed determine safe effective dosage treating
Язык: Английский
Процитировано
18
European Journal of Pharmacology, Год журнала: 2023, Номер 954, С. 175882 - 175882
Опубликована: Июнь 28, 2023
Glaucoma is a chronic and progressive neurodegenerative disease characterized by the loss of retinal ganglion cells visual field defects, currently affects around 1% world's population. Elevated intraocular pressure (IOP) best-known modifiable risk factor key therapeutic target in hypertensive glaucoma. The trabecular meshwork (TM) main site aqueous humor outflow resistance therefore critical regulator IOP. Fibrosis, reparative process excessive deposition extracellular matrix components contractile myofibroblasts, can impair TM function contribute to pathogenesis primary open-angle glaucoma (POAG) as well failure minimally invasive surgery (MIGS) devices. This paper provides detailed overview current anti-fibrotic therapeutics targeting glaucoma, along with their mechanisms, efficacy research progress from pre-clinical clinical studies.
Язык: Английский
Процитировано
18
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(11), С. 5749 - 5749
Опубликована: Май 25, 2024
Neurological disorders present a wide range of symptoms and challenges in diagnosis treatment. Cannabis sativa, with its diverse chemical composition, offers potential therapeutic benefits due to anticonvulsive, analgesic, anti-inflammatory, neuroprotective properties. Beyond cannabinoids, cannabis contains terpenes polyphenols, which synergistically enhance pharmacological effects. Various administration routes, including vaporization, oral ingestion, sublingual, rectal, provide flexibility treatment delivery. This review shows the efficacy managing neurological such as epilepsy, neurodegenerative diseases, neurodevelopmental disorders, psychiatric painful pathologies. Drawing from surveys, patient studies, clinical trials, it highlights alleviating symptoms, slowing disease progression, improving overall quality life for patients. Understanding mechanisms can open up possibilities using this plant individual needs.
Язык: Английский
Процитировано
8
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(7), С. 3603 - 3603
Опубликована: Март 22, 2024
The endogenous cannabinoid system (ECS) plays a critical role in the regulation of various physiological functions, including sleep, mood, and neuroinflammation. Phytocannabinoids such as Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinomimimetics, some N-acylethanolamides, particularly palmitoyethanolamide, have emerged potential therapeutic agents for management sleep disorders. THC, psychoactive component cannabis, may initially promote but, long term, alters architecture, while CBD shows promise improving quality without effects. Clinical studies suggest that modulates endocannabinoid signaling through several receptor sites, offering multifaceted approach to regulation. Similarly, palmitoylethanolamide (PEA), addition interacting with system, acts an agonist on peroxisome proliferator-activated receptors (PPARs). favorable safety profile PEA long-term use make them attractive alternative conventional pharmacotherapy. integration latter two compounds into comprehensive treatment strategies, together cognitive–behavioral therapy insomnia (CBT-I), represents holistic address multifactorial nature Further research is needed establish optimal dosage, safety, efficacy different patient populations, but offers hope improved general well-being.
Язык: Английский
Процитировано
7